https://journaljamps.com/index.php/JAMPS/issue/feedJournal of Advances in Medical and Pharmaceutical Sciences2026-11-20T09:27:11+00:00For Normal Processing[email protected]Open Journal Systems<p style="text-align: justify;"><strong>Journal of Advances in Medical and Pharmaceutical Sciences (ISSN: <a href="https://nsl.niscpr.res.in/ISSNPROCESS/issnassignedinfo.jsp">2394-1111</a>)</strong> aims to publish high quality papers (<a href="https://journaljamps.com/index.php/JAMPS/general-guideline-for-authors">Click here for Types of paper</a>) in all areas of Medical and Pharmaceutical Sciences. By not excluding papers based on novelty, this journal facilitates the research and wishes to publish papers as long as they are technically correct and scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled, OPEN peer-reviewed, open-access INTERNATIONAL journal.</p>https://journaljamps.com/index.php/JAMPS/article/view/916Effects of Supplementation with Vitamin D and Omega 3 Fish Oil on Doxorubicin-induced Liver and Kidney Damages2026-11-20T09:27:11+00:00Otu Martin OtuDoris IwuchukwuImaObong Christopher EttiNsikan MalachySamuel James Offor[email protected]<p>Doxorubicin is a medication used to treat various types of cancer. However, it can cause kidney and liver injuries. This study elucidates the effect of the combined use of vitamin D3 and omega-3 fish oil in reducing liver and kidney damage caused by doxorubicin toxicity. Thirty (30) Wistar albino rats were used for the experiment and randomly distributed into 5 groups, with 6 rats in each group. Group 1 rats were given normal saline for 28 days using an intragastric gauge (negative control group); group 2 rats were given normal saline orally for 28 days, followed by a single intraperitoneal injection of 20mg/kg body weight of doxorubicin 24 hours after the last dose of normal saline (positive control group); group 3 rats were given omega-3 fish oil at 400mg/kg body weight orally for 28 days, followed by a single intraperitoneal injection of 20mg/kg body weight of doxorubicin 24 hours later; group 4 rats were given vitamin D3 at 500IU/kg body weight orally for 28 days, followed by a single intraperitoneal injection of 20mg/kg body weight of doxorubicin 24 hours later; and group 5 rats were given omega-3 fish oil at 400mg/kg body weight + vitamin D3 at 500IU/kg body weight orally for 28 days, followed by a single intraperitoneal injection of 20mg/kg body weight of doxorubicin 24 hours later. Twenty-four (24) hours after the final administration of the drugs, the rats were anaesthetised using chloroform vapour in an enclosed jar, and blood samples were collected by cardiac puncture for biochemical analyses. Biochemical assessments of antioxidant enzymes (SOD, CAT, GPx), lipid peroxidation (MDA), hepatic and kidney parameters, and histopathological studies of the kidneys and liver were carried out. The results showed that vitamin D and omega-3 fish oil, when combined, protected the kidneys from doxorubicin toxicity and restored the normal cellular pattern in the liver. Combined vitamin D and omega-3 fish oil reduced the elevated urea levels caused by doxorubicin. Among the antioxidant enzymes, only the SOD level was reduced in the presence of doxorubicin, and this level increased following pretreatment with vitamin D combined with omega-3 fish oil. However, the levels of the other antioxidants, CAT and GPx, were not affected. In addition, some kidney and liver parameters were abnormally elevated, indicating toxicity in these organs following doxorubicin treatment. Combined vitamin D and omega-3 fish oil significantly reduced these levels. Furthermore, the blood cell counts and PCV, which were reduced following doxorubicin treatment, increased following treatment with vitamin D combined with omega-3 fish oil. The histopathological results corresponded with the biochemical assay results. In conclusion, vitamin D and omega-3 fish oil administered together possess hepatorenal protective properties against doxorubicin-induced toxicity.</p>2026-11-20T00:00:00+00:00Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.https://journaljamps.com/index.php/JAMPS/article/view/914Sézary Syndrome: A Case Report of a Variant of Cutaneous T-cell Lymphoma2026-11-19T11:58:21+00:00Christian E. Amiwero[email protected]Olanrewaju A. AjayiLere P. OluwadarePauline K. AkowunduIlemobayo Promise DayoOdutola I. Odetunde<p><strong>Aim:</strong> This case report highlights a rare variant of cutaneous T-cell lymphoma, known as Sézary syndrome, observed at Redeemers Health Village Hospital, a multispecialty tertiary academic centre in southwestern Nigeria.</p> <p><strong>Presentation of Case:</strong> The report describes a 36-year-old man diagnosed with stage IVB T4N3M1B2 (TNMB system) refractory Sézary syndrome, a rare and aggressive form of mycosis fungoides and a type of cutaneous T-cell lymphoma. The diagnosis was established on the basis of the patient’s medical history and findings from physical examination, histopathological analysis and blood film examination. This assessment revealed skin tumours, lymphadenopathy, particularly in the submental and axillary regions, visceral involvement indicated by splenomegaly, and erythroderma affecting more than 90% of the body surface area. Histopathology showed malignant T-cell infiltration in the skin, while immunophenotyping indicated CD3 and CD4 positivity (markers that are notably elevated in Sézary syndrome) and CD30 negativity. The blood film differential analysis identified more than 2,000 Sézary cells.</p> <p>In resource-limited countries in sub-Saharan Africa, analysis of an extended panel of markers is often restricted. However, a consensus reached in a study by Ulrickson <em>et al</em>. (2013) emphasised that the examination findings observed in this case are sufficient for diagnosing cutaneous lymphomas. The proposed treatment plan for this patient included topical corticosteroids, topical bexarotene and oral bexarotene.</p> <p><strong>Discussion:</strong> Sézary syndrome (SS) is a transformed form of mycosis fungoides that belongs to a family of cutaneous T-cell lymphomas (CTCLs). It is characterised by erythroderma affecting at least 80% of the body surface area, together with generalised lymphadenopathy and circulating malignant T cells (known as Sézary cells) in the peripheral blood. Diagnosing CTCL can be challenging, particularly in African settings, because of the rarity of the disease and its similarity to other dermatological conditions, such as psoriasis. Therefore, a high index of suspicion, together with clinical history and thorough physical examination, is essential for diagnosing CTCL and Sézary syndrome. Additional diagnostic tools include histopathological examination of skin lesions, blood film analysis, immunophenotyping and imaging studies. Following diagnosis, the National Comprehensive Cancer Network (NCCN, 2026) recommends initiating therapies that are well tolerated, have lower cumulative toxicity, reduce immunosuppression and offer greater efficacy over extended periods.</p> <p><strong>Conclusion:</strong> The choice of treatment depends on the disease stage at presentation and the presence or absence of targeted markers. Treatment options range from topical corticosteroids and ultraviolet B (UVB) phototherapy to psoralen plus ultraviolet A (PUVA) phototherapy, extracorporeal photopheresis (ECP), systemic chemotherapy and targeted monoclonal antibodies. Patients with Sézary syndrome have a poor prognosis and often experience a reduced quality of life, with a median survival of 1–4 years. However, mogamulizumab for patients with advanced Sézary syndrome, brentuximab for CD30-positive patients and bexarotene have been reported to improve response rates and increase progression-free survival.</p>2026-11-19T00:00:00+00:00Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.https://journaljamps.com/index.php/JAMPS/article/view/915Precision Pharmacotherapy for Paediatric Obesity: GLP-1 Receptor Agonists, Dual/Triple Agonists and MC4R-Targeted Therapy: A Structured Critical Narrative Review2026-11-19T12:42:04+00:00Ashraf T. Soliman[email protected]Fawzia AlyafeiAhmed KhalilNada AlaarajNoor HamedShayma Ahmed<p><strong>Background:</strong> Obesity in children and adolescents has become a global clinical problem that lifestyle treatment alone rarely resolves. Glucagon-like peptide-1 receptor agonists, multi-receptor incretin agonists and melanocortin-4 receptor agonists have changed what pharmacotherapy can achieve, yet the evidence for each class has developed in separate literatures with different designs, populations and outcome measures.</p> <p><strong>Aim and Scope:</strong> This review evaluates whether current evidence supports a precision approach in which drug selection for children and adolescents is matched to the aetiology of obesity, developmental stage and comorbidity, rather than applied uniformly.</p> <p><strong>Methods:</strong> A structured critical narrative review was conducted using bibliographic databases, a clinical trial registry and citation tracking. Randomised and single-arm trials, observational cohorts, evidence syntheses, guidelines, genetic studies and mechanistic research were appraised qualitatively for design, applicability and certainty, and synthesised thematically.</p> <p><strong>Findings:</strong> In adolescents with common obesity, randomised evidence supports clinically meaningful reductions in body mass index with liraglutide and, to a greater extent, semaglutide, with emerging randomised evidence for liraglutide in younger children. Weight regain after discontinuation, the scarcity of randomised follow-up beyond the medium term and the inability of routine clinical characteristics to predict response limit confidence in long-term benefit. Evidence for dual and triple agonists in young people remains confined to youth-onset type 2 diabetes and registered trials, so current expectations rest on adult data. Melanocortin-4 receptor agonism with setmelanotide is best supported in biallelic deficiencies of the leptin–melanocortin pathway, Bardet–Biedl syndrome and acquired hypothalamic obesity, whereas benefit in heterozygous pathway variants and several syndromic conditions is unproven. Glucagon-like peptide-1 receptor agonists appear to retain efficacy in some monogenic and syndromic forms, but supporting data are small and largely uncontrolled.</p> <p><strong>Implications:</strong> Genetic and hypothalamic diagnosis currently offers the most defensible basis for stratified prescribing, while pharmacogenomic and phenotypic prediction remain investigational. Growth, bone health, eating disorder risk and inequitable access require prospective surveillance.</p> <p><strong>Conclusions:</strong> Precision pharmacotherapy for paediatric obesity is feasible for defined aetiological subgroups but remains aspirational for most children with common obesity. Long-term, developmentally informed trials with aetiological stratification are needed.</p>2026-11-19T00:00:00+00:00Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.